T. Rowe Price Associates
AMPH icon

T. Rowe Price Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

T. Rowe Price Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
51,103
+6,200
+14% +$125K ﹤0.01% 2323
2026
Q1 		$880K Buy
44,903
+8,107
+22% +$198K ﹤0.01% 2219
2025
Q4 		$986K Sell
36,796
-238,426
-87% -$6.14M ﹤0.01% 2085
2025
Q3 		$7.34M Buy
275,222
+1,934
+0.7% +$49.9K ﹤0.01% 1301
2025
Q2 		$6.28M Sell
273,288
-267,933
-50% -$6.65M ﹤0.01% 1220
2025
Q1 		$15.7M Sell
541,221
-25,435
-4% -$812K ﹤0.01% 1007
2024
Q4 		$21M Sell
566,656
-2,238
-0.4% -$102K ﹤0.01% 989
2024
Q3 		$27.6M Sell
568,894
-15,012
-3% -$659K ﹤0.01% 922
2024
Q2 		$23.4M Sell
583,906
-638
-0.1% -$26.4K ﹤0.01% 917
2024
Q1 		$25.7M Sell
584,544
-2,413
-0.4% -$125K ﹤0.01% 917
2023
Q4 		$36.3M Buy
586,957
+17,245
+3% +$906K ﹤0.01% 789
2023
Q3 		$26.2M Buy
569,712
+63,404
+13% +$3.46M ﹤0.01% 855
2023
Q2 		$29.1M Buy
506,308
+37,888
+8% +$1.68M ﹤0.01% 841
2023
Q1 		$17.6M Sell
468,420
-320,750
-41% -$10.5M ﹤0.01% 947
2022
Q4 		$22.1M Sell
789,170
-19,561
-2% -$568K ﹤0.01% 884
2022
Q3 		$22.7M Buy
808,731
+645,917
+397% +$21.1M ﹤0.01% 871
2022
Q2 		$5.66M Buy
+162,814
New +$5.81M ﹤0.01% 1407

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Associates's AMPH Position: Q2 2026 in Review

T. Rowe Price Associates increased its Amphastar Pharmaceuticals (AMPH) stake by 14% in Q2 2026, buying an estimated $125K and bringing the position to 51,103 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

T. Rowe Price Associates first reported a position in AMPH in Q2 2022 and has held it in 17 quarters since. The position peaked at $36.3M in Q4 2023. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • T. Rowe Price Associates held 51,103 shares of Amphastar Pharmaceuticals worth $1.03M as of Q2 2026.
  • T. Rowe Price Associates bought 6,200 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $125K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2323 holding.
  • T. Rowe Price Associates first reported a position in Amphastar Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • T. Rowe Price Associates's Amphastar Pharmaceuticals position peaked at $36.3M in Q4 2023.
  • 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.